to 1 or 0. After the first appearance of grade 3 HFS or after the second appearance of grade 2 HFS, dose reduction should occur on reinitiation of treatment, as described in the capecitabine package insert (http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020896s016lbl.pdf). ...
In patients receiving combination therapy, median delivered capecitabine and docetaxel doses were 77% and 87% of the planned doses. Doses were mainly reduced because of hand-and-foot syndrome, diarrhoea or stomatitis. Treatment-related adverse effects occurred in 98% of patients in the combination...
The package insert recommends starting capecitabine at 2500 mg/m2/day in two divided doses in breast and colon cancer. Capecitabine has a well-established toxicity profile. The most common toxic effects are PPE, diarrhea, stomatitis, nausea and vomiting. It is regarded as well tolerated, and ...
administration of capecitabine, a non-crossreactive chemotherapy agent, in the adjuvant treatment of patients with tumors resistant to anthracycline and taxane provides a survival advantage. Reasons for the differing trial results are discussed below. The CREATEx results were so dramatic that several inv...